Press releases

2020  |  2019  |  2018  |  All
June 23, 2020
Compass Therapeutics Completes Reverse Merger and Closes $60 Million Private Placement
March 30, 2020
Compass Therapeutics Announces Publication of Data Demonstrating the Preclinical Efficacy and Safety of CTX-471, a Unique Fully Human Agonist of CD137
February 28, 2020
Compass Therapeutics to Present at the 40th Cowen Health Care Conference

Presentations and publications

View all
March 12, 2020 | JCI Insight
Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity
November 12, 2019 | SITC 2019
CTX-8371, a Novel Bispecific Targeting both PD-1 and PD-L1, is more Potent than Combination anti-PD-1 and PD-L1 Therapy and Provides Enhanced Protection from Tumors in vivo
November 12, 2019 | SITC 2019
A novel class of Innate Cell Engagers targeting NKp30

In the news

View all
April 6, 2020
Compass Therapeutics’ immuno-oncology prospect clears solid tumors in mice
December 11, 2019
Nature Reviews Drug Discovery: Immune agonist antibodies face critical test
December 4, 2019
BioWorld -Two’s companies: Crowd in bispecifics still growing as methodology sorted

Events

CICON
September 14 – 17
New York, NY
PEGS Europe
November 9 – 13
Lisbon, Portugal
SITC
November 10 – 15
National Harbor, MD
Stifel Healthcare Conference
November 17 – 18
New York, NY
Piper Sandler 32nd Annual Healthcare Conference
December 1 – 3
New York, NY
ASH
December 5 – 8
San Diego, CA